Literature DB >> 8466864

The human I alpha 1 and I alpha 2 germline promoter elements: proximal positive and distal negative elements may regulate the tissue specific expression of C alpha 1 and C alpha 2 germline transcripts.

N Lars1, S Paschalis.   

Abstract

Treatment of human splenic B lymphocytes with the mitogen Branhamella catarrhalis (BC) and transforming growth factor-beta 1 (TGF-beta 1) induces expression of germline Ig C alpha transcripts and class switching to this isotype. To further characterize the molecular mechanism by which TGF-beta 1 and mitogenic signals regulate the expression of unrearranged C alpha 1 and C alpha 2 genes, we have characterized the promoter elements that are responsible for the transcriptional activation of their corresponding germline genes using transient expression assays. We report here that both in the I alpha 1 and the I alpha 2 regions, maximal phorbol myristate acetate (PMA) and TGF-beta 1 responsiveness of the promoters can be conferred by 327 bp spanning the transcription initiation sites and a previously identified phylogenetically conserved region. The expression of these 327 bp segments is not restricted to the B cell lineage since they are also active in the erythroleukemia cell line K562 as well as the B cell lines Raji and DG75. Mutational analyses have demonstrated the importance of sequences within the 327 bp segment that contain a putative cyclic AMP responsive element binding protein (CREB) binding site for TGF-beta 1 and PMA responsiveness and putative PU-1 and Sp1 binding sites for basal promoter activity. Upstream distal elements that could negatively modulate the expression of the I alpha 1 and I alpha 2 promoters, particularly in non-B cells, have been identified. Three such elements were mapped between positions -352 to -243, -627 to -516, and upstream of position -731 respectively. The influence of these elements presumably contributes to the B cell specific expression of the I alpha 1 and I alpha 2 promoters. The I alpha 1 and I alpha 2 promoters were found to be functionally indistinguishable from each other with respect to their basal level of expression, and their responsiveness to TGF-beta 1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8466864     DOI: 10.1093/intimm/5.3.271

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  6 in total

1.  Regulation of c-Rel nuclear localization by binding of Ca2+/calmodulin.

Authors:  Asa Antonsson; Kate Hughes; Sofia Edin; Thomas Grundström
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

2.  CD40 engagement triggers switching to IgA1 and IgA2 in human B cells through induction of endogenous TGF-beta: evidence for TGF-beta but not IL-10-dependent direct S mu-->S alpha and sequential S mu-->S gamma, S gamma-->S alpha DNA recombination.

Authors:  H Zan; A Cerutti; P Dramitinos; A Schaffer; P Casali
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

3.  Calcium regulation of GM-CSF by calmodulin-dependent kinase II phosphorylation of Ets1.

Authors:  Hebin Liu; Thomas Grundström
Journal:  Mol Biol Cell       Date:  2002-12       Impact factor: 4.138

4.  Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.

Authors:  H Fahmi; C Cochet; Z Hmama; P Opolon; I Joab
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Selective killing of Smad4-negative tumor cells via a designed repressor strategy.

Authors:  Vidula Dixit; Rudy L Juliano
Journal:  Mol Pharmacol       Date:  2008-04-21       Impact factor: 4.436

6.  LMP1-augmented kappa intron enhancer activity contributes to upregulation expression of Ig kappa light chain via NF-kappaB and AP-1 pathways in nasopharyngeal carcinoma cells.

Authors:  HaiDan Liu; Hui Zheng; Zhi Duan; DuoSha Hu; Ming Li; SuFang Liu; ZiJian Li; XiYun Deng; ZhenLian Wang; Min Tang; Ying Shi; Wei Yi; Ya Cao
Journal:  Mol Cancer       Date:  2009-10-27       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.